This year’s Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, USA, and virtually from 2nd–6th June 2023 saw leading experts from around the world gather again to further discuss the most exciting updates in the field of lung cancer. Impressively, under the motto “partnering with patients: the cornerstone of cancer care and research” data with emphasis on practice-changing new studies, less toxic treatments, precision oncology and new ways to reduce collateral damage were discussed. This special issue provides current insights into perioperative strategies including promising new treatment options in early-stage, resectable non-small-cell lung cancer. Small-cell lung cancer is in the focus of the second chapter that highlights the feasibility of conducting biomarker-selected trials, the first-in-human results for bispecificT-cell engager therapy, and progression-free survival improvements withfirst-line pembrolizumab plus etoposide and platinum chemotherapy. Targeted approaches in advanced disease, including the newest results for EGFR tyrosinekinase inhibitors either as monotherapy or in combination with chemotherapy oran EGFR-MET bispecific antibody, as well as HER2, KRASG12C, BRAF and ROS1 inhibitors are outlined, too. Finally, this issue looks closely at stage IV lung cancer with Tumor Treating Fields therapy as an innovative, safe and effective option.

Asan additional feature, you will find an expert video interview with John Heymach on different conference highlights on our website.

Access and article directly (English):

Preface

Early-stage NSCLC: current insights into perioperative strategies

Small-cell lung cancer: novel agents & biomarkers

Targeted approaches in advanced disease

Stage IV lung cancer: miscellaneous treatment strategies

Full Report (English)

Downloadthe full report here!

Springer Medizin memo inOncology SPECIAL ISSUES are sponsored by an unrestricted medical education grant from Boehringer Ingelheim, BeiGene and ITM.